PD-L1 mAb (10F.9G2)™, InVivoPure

Endotoxin level ≤ 2 EU/mg

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and
plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed
death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation.
Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the
tumor microenvironment mediates tumor immune escape, and the development of anti-PD-
1/PD-L1 antibodies has recently become a hot topic in cancer immunotherapy.

The 10F.9G2 antibody is a monoclonal antibody specific for the mouse protein PD-L1
(Programmed Death Ligand 1), also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I
transmembrane protein that belongs to the B7 family of the immunoglobulin superfamily. It is
expressed on T cells, B cells, NK cells, dendritic cells, as well as on IFN-γ stimulated monocytes,
epithelial cells and endothelial cells. The interaction of PD-L1 with its receptor PD-1 on T cells
leads to the inhibition of T cell proliferation and cytokine production.
The anti-PD-L1 (10F.9G2) blocking antibody blocks interaction of PD-L1 with both of its binding
partners, PD-1 and CD80 (B7-1).

This antibody is produced exclusively under serum-free conditions from hybridoma and
purified with Protein-A or Protein-G affinity chromatography.

The product is for research use only and not for use in diagnostic or therapeutic procedures.